RGS16 and breast carcinoma: In light of the previous observations, reduced RGS16 expression is observed in the majority of breast cancers with mutations, which supports the existence of an association of phosphatidylinositol pathway activity regulation with RGS16 expression and breast cancer cell growth [51].